Navigation Links
AAHIVM Encouraged by TMC125 Approval
Date:2/4/2008

New HIV Medication Could Offer More Options for Treatment-Experienced

Patients

WASHINGTON, Feb. 4 /PRNewswire/ -- The American Academy of HIV Medicine (AAHIVM), a national organization of HIV-treating physicians, nurse practitioners and physician assistants, praised the accelerated U.S. Food and Drug Administration (FDA) approval of the anti-HIV medication TMC125 (etravirine), the first non-nucleoside reverse transcriptase inhibitor (NNRTI) to be introduced in nearly 10 years, and the first to show antiviral activity in treatment-experienced adult patients with NNRTI-resistant virus. NNRTI drug resistance occurs when HIV develops mutations that partially or completely stop the NNRTI from binding to the reverse transcriptase enzyme, causing the drug to lose effectiveness.

"With the FDA's accelerated approval of TMC125, we are encouraged by the increased treatment options that are now available for our patients," said AAHIVM Board Chair Jeffrey Schouten, MD, AAHIVS. "With antiretroviral therapy now in its third decade, HIV care providers have increasing concern over the cross-resistance of the NNRTI class. A patient resistant to one NNRTI is generally resistant to the other NNRTIs available, which significantly limits our options with our longtime and treatment-experienced patients. This drug may also be very useful for people who are infected with an NNRTI-resistant strain of HIV which is not uncommon. TMC125 offers HIV care providers another treatment option that could dramatically increase the capacity for continued success in their patients' long-term HIV care."

FDA-accelerated approval procedures allow for earlier approval of drugs that provide a meaningful therapeutic advantage over existing treatment for serious or life-threatening diseases. Longer-term data will be required before the FDA can consider traditional approval of TMC125. Dr. Schouten emphasized the importance of closely monitoring changes to any treatment regimen to recognize possible barriers to treatment adherence and to maximize potential for treatment success.

The American Academy of HIV Medicine is an independent organization of AAHIVM HIV Specialists(TM) and other health care professionals dedicated to advancing excellence in HIV/AIDS care. Through advocacy and education, AAHIVM is committed to supporting HIV clinicians and to ensuring better care for those living with HIV disease. AAHIVM is the only U.S. medical organization serving a membership of MDs, DOs, NPs and PAs, and providing all members the opportunity to credential as HIV Specialists(TM).


'/>"/>
SOURCE The AIDS Institute
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Families Encouraged to Enjoy Healthy Kids Fest January 12 at the Blue Cross RiverRink
2. Parents Encouraged to Set an Example for Their Teens and Help Stop Underage Drinking
3. New York City Cancer Patients, Survivors and Care Givers Encouraged to Keep Going(R)
4. Radiologists encouraged to look beyond cancer for clinically unseen diseases
5. FDA Accepts New Drug Application for Priority Review of Investigational HIV Treatment TMC125
6. FDA Accepts New Drug Application for Priority Review of Investigational HIV Treatment TMC125
7. Researchers query FDA about updating requirements for drug approval
8. Acura Pharmaceuticals, Inc. Announces Approval to List Shares on NASDAQ and Effective Feb. 4, 2008 a New Trading Symbol: ACUR
9. ATS Medical Provides Update on First Generation Tissue Valve Approval
10. Cell Therapeutics, Inc. (CTI) Cuts Net Operating Expenses 35% and Expands Commercial Team to Support Zevalin(R) Sales and Applications Seeking Two Product Approvals in 2009
11. China Pharma Holdings, Inc. Receives Chinese SFDA Approval for Generic Bumetanide Injection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from ... at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center ... care topics including advance care planning, healthcare costs and patient and family engagement. ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Those who have ... these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as ... Michigan, has released tools for healthy coping following a traumatic event. , Trauma sufferers ...
(Date:6/24/2016)... San Francisco, CA (PRWEB) , ... June 24, ... ... at CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has ... , self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... ... Haute Living, is proud to recognize Dr. Barry M. Weintraub as a prominent ... “the most beautiful women in the world, and the most handsome men, look ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016  Collagen Matrix, Inc., ("Collagen Matrix") the ... of collagen and mineral based medical devices for ... Bill Messer has joined the company as ... the growing portfolio of oral surgery, neurosurgery, orthopaedic ... joins the Collagen Matrix executive team as an ...
(Date:6/24/2016)... -- The Academy of Managed Care Pharmacy (AMCP) today ... allow biopharmaceutical companies to more easily share health care ... coverage decisions, a move that addresses the growing need ... The recommendations address restrictions in the sharing of product ... a prohibition that hinders decision makers from accessing HCEI ...
(Date:6/24/2016)... --  Pulmatrix, Inc ., (NASDAQ: PULM ), ... today that it was added to the Russell Microcap ... set of U.S. and global equity indexes on June ... for Pulmatrix," said Chief Executive Officer Robert Clarke ... in developing drugs for crucial unmet medical needs, and ...
Breaking Medicine Technology: